Genmab Change in Accounts Receivable 2010-2025 | GNMSF

Genmab change in accounts receivable for the twelve months ending June 30, 2025 was $-0.380B, a 10308.97% decline year-over-year.

  • Genmab annual change in accounts receivable for 2024 was $-0.231B, a 299.22% decline from 2023.
  • Genmab annual change in accounts receivable for 2023 was $0.116B, a 136.93% decline from 2022.
  • Genmab annual change in accounts receivable for 2022 was $-0.313B, a 83.39% increase from 2021.

Genmab Change in Accounts Receivable 2010-2025 | GNMSF

  • Genmab annual change in accounts receivable for 2024 was $-0.231B, a 299.22% decline from 2023.
  • Genmab annual change in accounts receivable for 2023 was $0.116B, a 136.93% decline from 2022.
  • Genmab annual change in accounts receivable for 2022 was $-0.313B, a 83.39% increase from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$249.7B
Amgen (AMGN)$159.6B
Gilead Sciences (GILD)$147.3B
Vertex Pharmaceuticals (VRTX)$101.1B
Bristol Myers Squibb (BMY)$98.2B
GSK (GSK)$81.6B
CSL (CSLLY)$68.5B
Regeneron Pharmaceuticals (REGN)$62.6B
Alnylam Pharmaceuticals (ALNY)$60.1B
Argenex SE (ARGX)$40.5B
Insmed (INSM)$27.4B
BioNTech SE (BNTX)$26.8B
Royalty Pharma (RPRX)$21.5B
Biogen (BIIB)$20.4B
Incyte (INCY)$16.8B
Illumina (ILMN)$15.5B
Genmab (GMAB)$15.4B
Ascendis Pharma (ASND)$11.8B
BioMarin Pharmaceutical (BMRN)$11.1B
QIAGEN (QGEN)$10.9B
Moderna (MRNA)$10.5B
Swedish Orphan Biovitrum (BIOVF)$10.3B
Exelixis (EXEL)$10.2B
Verona Pharma American Depositary Share (VRNA)$9B
Exact Sciences (EXAS)$8.9B
Bio-Techne Corp (TECH)$8.5B
Blueprint Medicines (BPMC)$8.3B
Halozyme Therapeutics (HALO)$8.3B
Roivant Sciences (ROIV)$8B
Guardant Health (GH)$7.3B